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Solid dispersionAbstract Purpose: To evaluate the physicochemical and in vitro characteristics of solid dispersions
using BCS II model drugs with Soluplus and one of its component homopolymers, PEG 6000.
Methods: Nifedipine (NIF) and sulfamethoxazole (SMX) of 99.3% and 99.5% purity, respectively,
were selected as BCS II model drugs, such that an improved dissolution rate and concentration in
the gastrointestinal tract should increase oral bioavailability. Soluplus is an amorphous, tri-block,
graft co-polymer with polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol (PCL:
PVAc:PEG6000) in the ratio 57:30:13. PEG 6000 (BASF) is a waxy material with melting point
of about 60 C. Solid dispersions were prepared using lyophilization or spray drying techniques.
Dissolution study, crystallinity content, and analysis for new chemical bond formation have been
used to evaluate the dispersed materials. Results: Although each polymer improved the drug disso-
lution rate, dissolution from Soluplus was slower. Enhanced dissolution rates were observed with
NIF solid dispersions, but the dissolution profiles were quite different due to the selected technique,
polymer, and dissolution medium. For SMX, there was similarity across the dissolution profiles
despite the medium, polymer, or applied technique. Each polymer was able to maintain an elevated
drug concentration over the three hour duration of the dissolution profile, i.e., supersaturation was
supported by the polymer. DSC thermograms revealed no melting endotherm, suggesting that the
drug is amorphous or molecularly dispersed. Conclusion: NIF and SMX solid dispersions were
successfully prepared by spray drying and lyophilization using Soluplus or PEG 6000. Each
polymer enhanced the drug dissolution rate; NIF dissolution rate was improved to a greater extent.1, Saudi
persions
Table 1 Material properties.
MW (g/mol)
Sulfamethoxazole 253
Nifedipine 346
Soluplus 118,000
PEG 6000
a True density, measured using heliu
b Reference Baird et al. (2010) and M
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when prepared using spray drying or lyophilDispersions with PEG 6000 had a faster dissolution rate due to its hydrophilic nature. DSC analysis
showed that no crystalline material exists in the dispersions.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Most new chemical entities in the pharmaceutical industry lack
the sufficient solubility in water (Fouad et al., 2011; Al-Obaidi
and Buckton, 2009; Ning et al., 2011; Emara et al., 2002) and,
thus, exhibit a slow dissolution rate and low oral bioavailabil-
ity. This conundrum drives scientists to develop new strategies
to overcome the repercussions of poor solubility. Enhancing
the solubility of different chemical substances by forming a
solid dispersion with a hydrophilic polymer is one of the most
promising methods. Different hydrophilic polymers have been
successfully used to enhance oral bioavailability by either
enhancing the dissolution rate and/or increasing the drug con-
centration in the aqueous medium (Emara et al., 2002; Tanno
et al., 2004; Konno et al., 2008).
Such solid dispersions also demonstrate an ability to main-
tain the amorphous state of a given drug during processing and
storage. The amorphous form of a drug has a 10–1000 fold
higher solubility than the crystalline form (Lakshman et al.,
2008). Keeping this amorphous state, in part, is a function of
drug concentration in the dispersion, indicating that some of
the drug will recrystallize after exceeding a particular drug-
polymer ratio (Weuts et al., 2011).
Polymers can possess different chemical and physical char-
acteristics, such as functional groups, molecular weight, melt-
ing temperature Tm, and glass transition temperature Tg.
Therefore, each polymer has a different ability to maintain dis-
persed drug at a particular drug-carrier ratio without recrystal-
lization (Mahieu et al., 2012).
An approach to understand drug-carrier relationship in a
solid dispersion took advantage of the thermodynamics
described by the Flory-Huggins Theory (Marsac et al., 2006,
2009). From this theory, a prediction of the polymer saturation
is calculated and proved to show promising results.
Sulfamethoxazole and nifedipine are the selected drug can-
didates for this study. The two drugs have a limited dissolution
rate due to lower solubility. However, forming a complex or
dispersing the drug in a hydrophilic carrier can often improve
the dissolution rate (Emara et al., 2002; O¨zdemir and Erkin,
2012).
In our previous experiments, the saturation limits of these
drugs in Soluplus and its component homopolymers were
investigated. PEG 6000 was found to exhibit a profoundDensity (g/cm3)a Mola
1.42 172.3
1.34 288.6
1.08 109,0
1.08 5555.
m pycnometry.
ahlin and Bergstro¨m (2013).
.A., Neau, S.H. Investigation of the in
ization. Saudi Pharmaceutical Journal (impact on the reduction in the SMX and NIF melting
endotherm (Altamimi and Neau, 2016). Polyvinyl caprolactam
(PCL) and polyvinyl acetate (PVAc) showed essentially no
reduction in the melting endotherm. Both polymers, also,
proved to be practically difficult to process due to their
hydrophobic nature (data not shown). Therefore, PVAc and
PCL were excluded from this study.
In this study, Soluplus as a parent polymer and one of its
component homopolymers, PEG 6000, are assessed for their
ability to form a solid dispersion by two different manufactur-
ing techniques, spray drying and lyophilization, as they are the
methods often used to produce solid dispersions. Stability,
morphology, in vitro release profile, and the release kinetics
of the dispersed materials are investigated.
2. Materials
Crystalline sulfamethoxazole (Fig. 1b) (SMX, Mw = 253.28
g/mol, density = 1.42 g/cm3) was purchased from Flavine
International Inc., Closter, NJ. Crystalline nifedipine
(Fig. 1a) (NIF, Mw = 346.34 g/mol, density = 1.34 g/cm
3)
was purchased from C.F.M. Co. Farmaceutica Milanese S.P.
A. (Milano, Italia). Soluplus (Fig. 1d) (Mw = 118,000 g/mol,
density = 1.08 g/cm3) and PEG 6000 (Fig. 1c) (Mw = 6000
g/mol, density = 1.08 g/cm3) were generous gifts from BASF
(Tarrytown, NY). Other properties of these materials are
presented in Table 1.
3. Methods
3.1. Preparation of a solid dispersion
3.1.1. Spray drying
Sulfamethoxazole and nifedipine with each polymer were pre-
pared in drug:polymer mass ratios of 1:1, 1:5, and 1:9. Each
drug with Soluplus or PEG 6000, at the selected mass ratio,
was dissolved in 250 ml of water/acetonitrile (1:5). Such solvent
ratio was chosen after extensive experimentations to ensure
using the same solution across the two preparation techniques.
Amagnetic bar was used to stir themixture until a clear solution
was observed. The solution was spray-dried using aMini Spray-
Dryer B-290 (Bu¨chi Labortechnik AG, Flawil, Switzerland).
The air flow was set to be 40 m3/h. For Soluplus mixtures,r volume (cm3/mol) DHfus (kJ/mo) Tm (K) Tg (K)
28.7 443 289b
36.5 447 316
00 – – 347
6 1072 333 235
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In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 3the solution was sprayed with an inlet air temperature of 90 C
and a flow rate of 25%. For PEG 6000 mixtures, the inlet tem-
perature was 60 C with a flow rate of 20%.
3.1.2. Lyophilization
Sulfamethoxazole and nifedipine with each polymer were pre-
pared in drug:polymer mass ratios of 1:1, 1:5, and 1:9. Each
drug with Soluplus or PEG 6000, at the selected mass ratio,
was dissolved in 250 ml of water/acetonitrile (1:5). A magnetic
bar was used to stir the mixture until a clear solution was
observed. The solution was placed in a 80 C freezer for
24 h. The frozen solutions were then placed in an AdVantage
XL-70 freeze dryer (Virtis, Gardiner, NY) at a condenser tem-
perature of 60 C and reduced pressure of 20 mbar for at
least 24 h. The shelf temperature was 40 C in the first day
for primary drying. The lyophilized mixtures were taken from
the lyophilizer and placed in a desiccator at 25 C the following
day for secondary drying.
3.2. Differential scanning calorimetry
Thermal analysis was conducted using a TA 2910 DSC (TA
Instruments, New Castle, DE, USA) at a scan rate of 10 C/
min. Samples of 3–7 mg were weighed and placed in an alu-
minum pan and an aluminum lid was crimped to form a her-
metic seal. The DSC was calibrated for temperature and
enthalpy with indium (100% pure, melting point 156.60 C,
heat of fusion 6.80 cal/g). The sample and reference cells were
purged with nitrogen at 50 ml/min. The results were analyzed
using Thermal Advantage 1.1 A software.
3.3. Fourier transform infrared spectroscopy
The infrared spectrum of the drugs, the polymers, and their
spray-dried and lyophilized mixtures were obtained using a
Nicolet iS10 Fourier transform infrared (FTIR) spectrometer
(Thermo Fisher Scientific, Madison, WI, USA). The materials
were prepared as KBr pellets and spectra were collected across
4000–600 cm1 wave number using 64 scans and 2 cm1 reso-
lution (Tanno et al., 2004; Sathigari et al., 2012).
3.4. Drug dissolution studies
3.4.1. Dissolution tests
In vitro dissolution tests of SMX, NIF, and solid dispersions
were conducted in 900 ml of SGF or SIF at 37.0 ± 0.2 C
using a Distek model 2100C (Distek, North Brunswick, NJ)
with paddle rotation of 100 rpm. At designated time points,
samples were drawn and filtered through a 0.45 lm in-line fil-
ter using a Distek model 2230A autosampler, and then ana-
lyzed using UV spectrophotometry at 260 and 240 nm for
SMX and NIF, respectively. Each experiment was conducted
at least in triplicate (Tao et al., 2009).
3.4.2. Data analysis of release data
3.4.2.1. Mathematical models of release kinetics. Drug-polymer
mixture release kinetics were evaluated using zero-order, first-
order, Hixson-Crowell, Higuchi, and Ritger-Peppas model
equations (Khan et al., 2012; Shoaib et al., 2006; Costa and
Sousa Lobo, 2001).Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (3.4.2.1.1. Zero-order kinetic model. If a plot of the cumula-
tive amount of drug released as a function of release time pre-
sents linear data, zero-order kinetics is suggested and the
release rate is independent of the drug concentration.
Mt
M1
¼Mo þ kot ð1Þ
whereMo,Mt, andM1 are the amount of drug released at the
beginning, at time t in the release period, and the total mass of
drug released at infinite time (typically taken to be the mass of
drug available in the sample), respectively. The coefficient ko is
the zero order rate constant.
3.4.2.1.2. First-order kinetic model. If a plot of the negative
of the log (base e) of 1 minus the cumulative fraction of drug
released versus time is linear, drug is said to undergo first-order
release. Eq. (2) shows the dependence of the release rate on the
drug concentration.
 ln 1 Mt
M1
 
¼ k1t ð2Þ
3.4.2.1.3. Higuchi kinetic model. Plotting the cumulative
amount of the released drug as a function of the square root
of the release time renders linearized data if the drug is released
by kinetics described by the Higuchi model. The model was
developed to describe drug release from a matrix that remains
intact during drug release:
Mt
M1
¼Mo þ kH
ﬃﬃ
t
p ð3Þ
where kH is the Higuchi rate constant.
3.4.2.1.4. Hixson-Crowell kinetic model. The Hixson-
Crowell kinetic model applies if a plot of the difference
between the cube root of the mass of drug initially in a matrix,
i.e., M1, and the cube root of the mass of drug remaining in
that matrix at time t, M1 Mt, as a function of release time
presents linearized data. The model describes drug release
from a spherical matrix that erodes or dissolves proportionally
across its surface area over time to release the drug.
ðM1Þ1=3  ðM1 MtÞ13 ¼ kHCt ð4Þ
kHC is the Hixson-Crowell rate constant.
3.4.2.1.5. Ritger-Peppas kinetic model. The plot for this
kinetic model presents the fraction of drug released from the
solid dosage form as a function of release time.
Mt
M1
¼ kRPtn ð5Þ
where kRP is the Ritger-Peppas rate constant. The exponent, n,
can provide some insight into the release mechanism, with dis-
solved drug diffusion from an essentially intact matrix at its
low value (typically about 0.5) and polymer relaxation (hydra-
tion, swelling, and possibly gelling of the polymer) at the high
extreme (typically about 1.0). At values between these
extremes, the release mechanism is described as anomalous,
indicating that drug release is achieved by a combination of
mechanisms or by an undefined mechanism.
3.4.2.2. Analysis of the drug release data. Sigma Plot 2002 for
Windows, version 12.0 (SPSS, Inc., Chicago, IL) was used to
analyze and fit equations to the release data. The variables
were predicted and p< 0.05 was considered significant
(Huang et al., 2006).vitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
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Figure 1 Chemical structures of a. nifedipine, b. sulfamethoxazole, c. polyethylene glycol, and d. Soluplus.
4 M.A. Altamimi, S.H. Neau3.4.2.3. Comparison of release profiles. To evaluate the similar-
ity of in vitro release profiles before and after the stability
study, the similarity factor, f2, will be calculated. The similarity
factor, as defined in Eq. (6) is based on the difference in drug
percent dissolved between the test and the reference product at
specific time points:
f2 ¼ 50  log 1þ
1
n
 Xn
i¼1
jRi  Tij2
 !05
 100
8<
:
9=
; ð6Þ
where n is the number of time points, Ri is the percentage of
drug released from the reference product, and Ti is the percent-
age released from the comparison product at different time
points. The f2 value is 50–100 for similarity and less than 50
for dissimilarity in the dissolution profiles (Ning et al., 2011;
Costa and Sousa Lobo, 2001; Flanner, 1996).
3.5. Drug stability studies
3.5.1. Storage conditions for stability studies
Pure drug, pure polymer, and solid dispersions will be stored
under 50 C/0% RH and 25 C/0% RH conditions. Thermal
analysis was conducted after six months by DSC to evaluate
the degree of crystallinity of the drug following each storage
condition (Tanno et al., 2004).
4. Results and discussions
4.1. Differential scanning calorimetry
The melting endotherm of each drug and polymer is found in
Fig. 2. Sulfamethoxazole has a melting point of 169.87 C,
nifedipine has a melting point of 173.05 C, Soluplus has a
Tg around 70 C, and PEG 6000 is semi crystalline with Tg
around 22 C (not shown in the figure) and a melting point
of 60 C.Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (4.1.1. Spray dried solid dispersion
The DSC analysis for SMX-Soluplus at different ratios is
found in Fig. 3a. The melting endotherm for SMX is 169.9 C;
however, no melting endotherm was evident at any drug-
polymer ratio in this experiment. This analysis proves that Solu-
plus, even at a 1:1 mass ratio, successfully dispersed SMXwith
no trace of crystallinity when spray drying method was used.
The Tg for the dispersed mixtures is shifting toward the original
glass transition temperature of neat Soluplus as the polymer
content increases. This shift reveals an effective interaction
between the drug and the polymer. Such a change inTg indicates
that the drug works as a plasticizer (Nagy et al., 2012). Gordon-
Taylor (G-T) and Fox equations have been developed to predict
the glass transition temperature of blends. However, the exper-
imental Tg deviates from the Tg predicted by these equations.
Such deviation is attributed to non-ideal mixing due to an unex-
pected change in volume (Weuts et al., 2011; Sathigari et al.,
2012; Witold et al., 2008; Forster et al., 2001). Andronis et al.,
showed that an increase in moisture content substantially
reduced the glass transition temperature of indomethacin
(Vlassios Andronis and George, 1996). The moisture uptake
was larger for the amorphous form of the drug. A significant
reduction in the crystallization temperature as themoisture con-
tent increased is reported (Grisedale et al., 2012). In this work,
focus is on the appearance of the melting endotherm at different
polymer ratios. Each of the preparation methods renders dis-
persed materials with different moisture contents. However, it
has been reported that the freeze drying method might induce
drug crystallization. Such induction happens during the freezing
step. In that step the solution will not freeze instantaneously
allowing the water to form crystals. Finally, the sample freezes
as a material that is amorphous, crystalline, or a combination
of the two. The percentage of the solvent that does not freeze
is considered bound solvent (Abdelwahed et al., 2006). In the lit-
erature, however, both methods, demonstrated a moisture con-
tent of up to 5% (Maa et al., 1998).vitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 2 DSC thermograms for (top to bottom) sulfamethoxazole, PEG 6000, Soluplus, and nifedipine.
Figure 3a DSC thermograms of sulfamethoxazole:Soluplus spray dried mixtures at a mass ratio of 1:1, 1:5, and 1:9.
In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 5DSC analysis for the SMX-PEG 6000 dispersions prepared
using spray drying is found in Fig. 3b. The melting endotherm
of PEG 6000 was around 57 C, whereas no melting endotherm
was found for SMX. It is obvious that the large meltingPlease cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (endotherm of PEG 6000 in the mixture enlarges the y-axis
and, thus, obscures any melting endotherm for SMX at higher
temperatures. However, there was no melting endotherm for
SMX at temperature ranging from 75 to 160 C.vitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 3b DSC thermograms of sulfamethoxazole:PEG 6000 spray dried mixtures at mass ratios of 1:5 and 1:9.
Figure 4a DSC thermograms of nifedipine:Soluplus spray dried mixtures at mass ratios of 1:1, 1:5, and 1:9.
6 M.A. Altamimi, S.H. NeauWhen the drug dissolves in the polymer and forms a solid
solution, or when drug is dispersed in the polymer carrier as
amorphous material, no drug melting endotherm can be
detected. The slight change in PEG 6000melting might be attrib-Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (uted to the dispersed drug or residual moisture effect. In addi-
tion, PEG 6000 exists in an extended or folded form. The latter
will render a shoulder that precedes the melting of the extended
form of the polymer (Corrigan et al., 2002). This shoulder isvitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 4b DSC thermograms for nifedipine:PEG 6000 spray dried mixtures at mass ratios of 1:5, and 1:9.
Figure 5a DSC thermograms for sulfamethoxazole:Soluplus lyophilized mixtures at mass ratios of 1:1, 1:5, and 1:9.
In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 7attributed to the polymer chains that have folded during drying.
Observed broad peaks at temperatures above 160 C have been
reported elsewhere (Fouad et al., 2011; Guyot et al., 1995). ThePlease cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (collected materials for 1:1 ratio were excluded. The material
was sticking to the walls with high solvent content, unlike the
other formulation where fine dry powder was collected.vitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 5b DSC thermograms for the sulfamethoxazole:PEG 6000 lyophilized mixtures at mass ratios of 1:1, 1:5, and 1:9.
Figure 6a DSC thermograms for the nifedipine:Soluplus lyophilized mixtures at mass ratios of 1:1, 1:5, and 1:9.
8 M.A. Altamimi, S.H. NeauThermal analyses of spray dried NIF-Soluplus samples
are found in Fig. 4a. A sharp melting endotherm was not
found at any mass ratio. Negligible endothermic events were
found in the thermograms for the mixtures at 1:1 and 1:5 massPlease cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (ratios that might be due to traces of crystalline NIF that did
not dissolve in the polymer. An increase in the glass transition
temperature with higher polymer ratios was observed, with a
similar trend found for SMX-Soluplus mixtures. SMX andvitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 6b DSC thermograms for nifedipine:PEG 6000 lyophilized mixtures at mass ratios of 1:1, 1:5, and 1:9.
Figure 7a DSC thermograms for SMX mixtures with Soluplus and with PEG 6000 at a mass ratio of 1:9 stored for six months at 0%
RH and 25 C.
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Figure 7b DSC thermograms for NIF mixtures with Soluplus and with PEG 6000 at a mass ratio of 1:9 stored for six months at 0%
RH and 25 C.
10 M.A. Altamimi, S.H. NeauNIF have melting endotherms around 170 C; however, the
thermodynamic driving force for solubility in Soluplus is lar-
ger for SMX than for NIF (Altamimi and Neau, 2016). There-
fore, it was expected that Soluplus would dissolve SMX to a
larger extent than NIF when making a solid dispersion.
Thermograms for the spray dried mixtures of NIF-PEG
6000 at 1:5 and 1:9 mass ratios reveal the absence of the
NIF melting endotherm, indicating a complete conversion of
crystalline NIF to its amorphous form or complete molecular
level dispersion of the drug in the polymer matrix, see Fig. 4b.
4.1.2. Lyophilized solid dispersions
Thermograms for the lyophilized SMX-Soluplus and SMX-
PEG 6000 mixtures are found in Figs. 5a and 5b, respectively.
The melting endotherm was obvious in the thermogram for
each dispersion with the 1:1 mass ratio, indicating the presence
of crystalline drug. The melting endotherm is not evident in the
thermograms for mixtures with higher polymer levels.
In Figs. 6a and 6b, the melting endotherm was absent
except for 1:1 ratio. In particular, Fig. 6a, a recrystallization
peak was found before the melting of nifedipine.
The preparation methods for the solid dispersion mixtures
are of crucial importance. The detectable sharp melting
endotherm for the lyophilized 1:1 mixture of NIF or SMX
with PEG 6000 proves the superiority of spray drying to form
solid dispersions. The freezing step in lyophilization fixes the
solution components in space because the viscosity of thePlease cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (liquid would rise quickly, whereas spray drying should allow
a greater time frame over which rearrangement of solute mole-
cules can take place as the solvent evaporates from each
sprayed drop. In the freezing step, bound water does not
freeze. This bound water will not sublime in the reduced pres-
sure environment (Abdelwahed et al., 2006), but is more likely
to be removed during secondary drying in a lyophilizer or with
sufficient extended time in the desiccator at room temperature.
In spray drying, bound water should evaporate due to the
higher temperature providing sufficient energy to break the
bonds of water with the polymer hydrophilic functional
group(s) that lead to bound water.
Water in the lyophilized mixture is more likely found in the
amorphous part of the drug but its presence can induce crystal-
lization. Such induction occurs due the greater mobility that
the water gives to the amorphous form of the drug (Vlassios
Andronis and George, 1996; Grisedale et al., 2012). For every
SMX:Soluplus ratio, single detectable Tg was missing in lyo-
philized mixtures, which also indicates less efficient mixing of
the two in the lyophilized mixtures.
When SMX- or NIF-PEG 6000 samples were lyophilized,
the solid dispersion successfully maintained the amorphous
form of the drug at higher polymer levels in the samples, with
mass ratios of 1:5, and 1:9 (Figs. 5b and 6b, respectively). At
the 1:1 mass ratio, the melting endotherms for each drug were
detected, exhibiting a trend similar to that observed with
Soluplus. It is important to note that, polyethylene glycol,vitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 7c DSC thermograms for SMX mixtures with Soluplus and with PEG 6000 at a mass ratio of 1:9 stored for six months at 0%
R.H. and 50 C.
In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 11at different molecular weights, has been used to form eutectic
mixtures (Vippagunta et al., 2007). In their study, they have
found mixing PEG with a crystal drug at ratios around the
eutectic point showed similar improvement in the dissolution
rate. Furthermore, Law et al., presented unchanged PXRD
patterns for PEG:fenofibrate at or around the eutectic point
(Law et al., 2003). Therefore, we expect an improvement in
the dissolution rate at the selected ratios weather or not we
formed an eutectic mixture (will be discussed later in this
paper).
4.2. Drug stability studies
The drug and the 1:9 mass ratio drug:polymer mixtures, pre-
pared using either spray drying or lyophilization techniques,
are subjected to a 6 month study under different temperature
conditions. No recrystallization was found with either of the
dispersed drugs (see Figs. 7a–7d).
4.3. Fourier transform infrared spectroscopy
The energy in the infrared IR region is not sufficient to excite
electrons of a molecule. Upon absorption, however, the energy
is enough to stretch or bend the bonds of a particular mole-
cule. Therefore, the vibrational frequencies of certain chemical
bonds involving specific atoms are detected using IR spec-Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (troscopy (Watson, 2005). The IR spectrum provides the finger-
print of different chemical substances and specifically can
detect the presence of newly formed bonds when the molecules
are dispersed in polymers (Huang et al., 2008).
The IR spectrum for crystalline SMX is found in Fig. 8a.
For SMX, the first three distinctive peaks starting from the
higher wave numbers are attributed to NAH vibrations.
NH2 stretching shows sharp peaks at 3468 and 3378 cm
1
for asymmetric and symmetric stretching, respectively. The
detected peak at 3299 cm1 is attributed to NAH stretching
in the amide functional group. CAH stretching shows a clear
peak at 3144 cm1 (Takasuka and Nakai, 2001). CAC and
CAN vibrational stretching is assigned to the peaks at 1597
and 1502 cm1, respectively. The peaks at 1267, 1092, and
1043 cm1 are attributed to the SO2 stretching vibrations
(Vijaya Chamundeeswari et al., 2014).
The crystalline NIF IR spectrum is found in Fig. 8a. The
distinctive vibrational bands at 3332, and 1682–1690 cm1
are attributed to NAH and C‚O, respectively (Huang et al.,
2008). The peak at 2954 cm1 is assigned to CAH aliphatic
stretching. NO2 symmetric stretching is found at 1350 cm
1
(Chan et al., 2004).
Soluplus showed a broad peak centered at 3463 cm1 that
is attributed to OAH vibrational stretching. CAH stretching is
found to be the peak at 2933 cm1. Peaks at 1739, and
1635 cm1 are attributed to C‚O in the ester and tertiary
amide, respectively (Homayouni et al., 2014). The ethervitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 7d DSC thermograms for NIF mixtures with Soluplus and with PEG 6000 at a mass ratio of 1:9 stored for six months at 0%
RH and 50 C.
12 M.A. Altamimi, S.H. NeauCAOAC has a distinctive peak at 1483 cm1 (Shamma and
Basha, 2013).
PEG 6000 showed peaks at 3439, 2887, and 1113 cm1 that
are attributed to OAH, CAH and CAOAC vibrational
stretching (Vijaya Kumar and Mishra, 2006; Ruan et al.,
2005; Sawhney et al., 1993; Van den Mooter et al., 1998).
The observed peak wave numbers in the IR spectra of each
functional group are summarized in Table 2, along with the
wave number found in the literature.
There are different functional groups in SMX and NIF that
are capable of donating or accepting protons to form hydrogen
bonds. The primary amine and the nitrogen in the sulfonamide
group in SMX can donate protons to higher electronegativity
atoms. In fact, SMX is expected to form hydrogen bonding
with itself when the two oxygen atoms associated with the sul-
fur atom (SO2) accept the protons. Also, the nitrogen atom in
the isoxazole ring can also act as a proton acceptor.
The proton donor site in NIF is the nitrogen in the dihy-
dropyridine ring. The oxygens in the carbonyl functional
groups are proton acceptors. The NO2 functional group is
expected to have no hydrogen bonding capability (Huang
et al., 2008). Soluplus has carbonyl, hydroxyl, and ether func-
tional groups capable of hydrogen bonding. PEG 6000 like-
wise can donate or accept a proton through the hydroxyl
groups and the oxygen in each of the ether groups.
Fig. 8b shows the IR spectrum of spray dried (S) and lyo-
philized (L) SMX with either Soluplus or PEG 6000. ForPlease cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (the SMX-Soluplus solid dispersion, the four distinctive peaks
between 3000 and 3500 cm1 for crystalline SMX have disap-
peared. This disappearance is ascribed to the disruption of
hydrogen bonding between the SMX molecules and forming
new bonds with the polymer. The shift in the broad peak from
3463 cm1 for neat Soluplus to 3448 and 3455 cm1 for the
spray dried and lyophilized SMX-Soluplus mixtures is postu-
lated to be the OAH stretching vibrations which strongly indi-
cate hydrogen bond formation with either the primary amine
or one of the oxygen atoms found on the sulfur. There is a
small but detectable shoulder at 3230 cm1, which might indi-
cate a stretch of the amide NAH in SMX. The two carbonyl
peaks at 1739, and 1635 cm1 have shifted to lower wave num-
bers in the mixture. The new peaks are evident at 1736, 1625,
and 1621 cm1, suggesting a new hydrogen bond stretching
with the primary amine and amide NAH.
The broad peak at 3439 cm1 for neat PEG 6000 has
shifted to 3443 cm1 for spray dried and lyophilized dispersed
mixtures. Such a shift is postulated to be stretching in the
hydrogen bond of the hydroxyl groups of the polymer. The
ether group shifted to 1112 cm1 for the dispersed mixtures.
This slight difference might not be compelling for hydrogen
bond formation; however, the difficulty to demonstrate the
hydrogen bond formation with PEG 6000 has been reported
elsewhere (Van den Mooter et al., 1998).
Fig. 8c shows the IR spectrum of spray dried (S) and lyo-
philized (L) NIF with either Soluplus or PEG 6000. Forvitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 8a FTIR analysis for the used materials.
In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 13NIF-Soluplus solid dispersion, the broad peak for Soluplus
has shifted to 3459 cm1. The shift in this peak is attributed to
hydrogen bond formation between the carbonyl group found
in NIF with the hydroxyl group found in Soluplus. The small
shoulder at 3285 is postulated to be NAH stretching of NIF
due to hydrogen bond formation with Soluplus carbonyl or
ether groups. The carbonyl groups of NIF exhibit sharp peaks
at 1682–1690 cm1, whereas Soluplus exhibits distinctive car-
bonyl peaks at 1739 and 1635 cm1. For the dispersions, how-
ever, the peak moved higher to 1701 cm1 which is attributed
to the stretch in the C‚O when engaged in hydrogen bond
formation with the polymer. Huang et al., suggested that the
peak at 1701 cm1 indicates formation of amorphous NIF,
and the carbonyl stretch for NIF at 1702–1728 cm1 should
indicate hydrogen bond formation (Huang et al., 2008). How-
ever, forming an amorphous drug is expected and it was previ-
ously confirmed using DSC analysis. In addition, having
carbonyl groups in both the polymer and the drug might
obscure the shift of the stretch in the NIF carbonyl groups.
Soluplus carbonyl group peaks have shifted to 1736, 1636
and 1739, 1632 for spray dried and lyophilized mixtures,
respectively.
The change in the wave number of the PEG 6000 broad
peak from 3439 to 3443 cm1 in NIF-PEG 6000 dispersions
is similar to the one found for SMX-PEG 6000 dispersions,
which is due to stretching in the hydroxyl groups of the poly-
mer. The small shoulder at 3327 cm1 is expected to be the
vibrational stretch of NAH upon hydrogen bond formation
with the polymer. The carbonyl group exhibits distinctive
peaks at 1682–1690 cm1. The absence of any stretching indi-
cates that there was no hydrogen bond between the carbonyl
group and the polymer.Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (The FTIR studies exhibit compelling evidences of change in
the vibrational stretching within the different dispersions. The
missing distinctive peaks, for instance, between pure SMX and
SMX in dispersions are attributed to the inclusion of the drug
in the polymer cavity (Guyot et al., 1995). Using the drug in
smaller mass ratios with the polymer might prevent the instru-
ment from acknowledging the vibrational stretching.
Between spray drying and lyophilization there were no sig-
nificant differences in the IR spectra. The lack of any differ-
ences indicates that the preparation methods used to form
solid dispersion have comparable efficiency.4.4. Drug dissolution studies
It is crucial to test the dissolution characteristics of the drug
and the drug-polymer mixtures prepared using different meth-
ods. As described in the method section, the preparation
parameters were kept exactly the same, except when final prod-
ucts were made. Therefore, we expect any differences to be due
to the preparation methods only. Two different enzyme-free
media were selected, namely simulated intestinal fluid SIF
(pH = 6.8 ± 0.1) and simulated gastric fluid SGF
(pH = 1.2 ± 0.1) at 37 ± 0.2 C. The model drugs, only, were
tested in water for comparison. Each drug is ionized at a par-
ticular pH range or ranges. Sulfamethoxazole has two pKa
values, namely 1.7 and 5.7. At pH above 5.7 SMX becomes
anionic losing the proton on ASO2ANHA group. In very
acidic conditions, with pH less than 1.7, the cationic form of
SMX is found by protonating the aromatic NH2 group. For
pH between 1.7 and 5.7 SMX is expected to be uncharged
(Gokturk et al., 2012; Lucida et al., 2000). For NIF, however,vitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Table 2 The characteristic vibrational stretching wave numbers for functional groups found in the materials and their corresponding
values from the literature.
Assignments Literature
SMX wave
numbers
(cm1)
Experimental
SMX wave
numbers
(cm1)
Literature
NIF wave
numbers
(cm1)
Experimental
NIF wave
numbers
(cm1)
Literature
Soluplus
wave
numbers
(cm1)
Experimental
Soluplus
wave numbers
(cm1)
Literature
PEG 6000
wave
numbers
(cm1)
Experimental
PEG 6000
wave numbers
(cm1)
as,1(NAH) 3470a,
3467b
3468 – – – – – –
s,1(NAH) 3381a,
3378b
3378 – – – – – –
2(NAH) 3301b 3299 3332c,
3330d
3332 – – – –
OAH – – 3449e 3463 3445g, 3446h,
3510k
3439
CAH 3145a,
3143b
3144 2953d 2954 2928e 2933 2887g, 2889h,
2880k
2887
CAC 1619b,
1597b
1621, 1597 – – – – – –
C‚O – – (1679,
1689)c
(1682, 1690) (1739, 1643)e (1739, 1635) – –
(1679,
1682)d
(1736, 1635)f
CAOAC – – – – 1477e 1483 1110g,l 1113
N‚O – – 1530d 1530 – – – –
S‚O 1266b,
1091b
1267, 1092 – – – – – –
(a, as) are asymmetric and symmetric vibrational stretching.
(1, 2) are primary and secondary amines.
a Reference Takasuka and Nakai (2001).
b Reference Vijaya Chamundeeswari et al. (2014).
c Reference Huang et al. (2008).
d Reference Chan et al. (2004).
e Reference Homayouni et al. (2014).
f Reference Shamma and Basha (2013).
g Reference Vijaya Kumar and Mishra (2006).
h Reference Ruan et al. (2005).
k Reference Sawhney et al. (1993).
l Reference Van den Mooter et al. (1998).
14 M.A. Altamimi, S.H. Neauthe pKa was reported to be around 1 (Zhang et al., 1997;
Zendelovska et al., 2006). Therefore, except in very acidic con-
dition of pH 6 1.0, NIF is expected to be predominantly
uncharged.
A three hour dissolution study proved to be sufficient to
identify the highest drug concentration (Konno et al., 2008).
Reduction in the drug concentration due to recrystallization
can, therefore, be identified (Tanno et al., 2004).
In Fig. 9a, pure SMX exhibited a high dissolution rate in
water and SIF. Spray dried SMX with PEG 6000 revealed
the higher dissolution rate with nearly complete drug dissolu-
tion in the first 15 min of the dissolution profile. The concen-
tration was maintained at 91% at 180 min, which suggests a
slight precipitation of SMX under these conditions. SMX-
Soluplus spray dried mixture exhibits a slower release rate
than does the pure SMX. Soluplus is an amphiphilic polymer
that might contribute to the dissolution with a slower rate due
to its own slower dissolution rate. The drug release profile for
Soluplus, however, provided 85% release at 180 min. It is
important to note that SMX-Soluplus spray dried mixture
showed a potential of continual increase in SMX concentra-
tion after 3 h period.Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (In Fig. 9b, the dissolution rate and the percentage release of
pure SMX in SGF are lower than the one found in SIF. It sug-
gests that the cationic form of SMX has a lower dissolution
rate and overall solubility than the anionic form. PEG 6000
was effective in enhancing the drug release rate and in main-
taining the drug concentration over the experimental time per-
iod. SMX-Soluplus spray dried mixture provided a complete
dissolution of the drug after 150 min in SGF.
In Fig. 9c, SMX and the lyophilized mixtures exhibited
high, but similar, dissolution rates. The lyophilized product
showed an enhanced dissolution rate for SMX-Soluplus mix-
ture with similar tendency for greater improvement in the drug
concentration with time. A similar trend was observed for
SMX-PEG 6000 with a slight reduction in drug concentration
after 120 min, which might be attributed to precipitation.
In Fig. 9d, the dissolution rate for lyophilized SMX-PEG
6000 in SGF is slower than in SIF, whereas the SMX-
Soluplus mixture maintained a complete dissolution level
for the last 90 min. The two polymers maintain higher drug
concentrations than the pure drug can achieve.
The spray dried mixtures are more sensitive to the ioniza-
tion form of SMX. It has been reported that at high Soluplusvitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 8b FTIR analysis for SMX-polymer mixtures (S denotes spray dried, and L denotes lyophilized).
In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 15concentrations the drug should exhibit slower dissolution rate
due to the increase in the medium viscosity (Homayouni et al.,
2014). Furthermore, Soluplus forms micelles (Yu et al., 2013)
and it was suggested that polymers that form micelles with
higher loading and lower polymer concentration in the med-
ium should induce less interaction between the drug and the
polymer and, thus, impose greater pressure on the micelle wall.
Therefore, they enhance the dissolution rate (Yu et al., 2013;
Huh et al., 2005), but might exceed the capacity of the micelles
to contain the poorly soluble drug. In contrast, when the PEG
6000 ratio increased, a large increase in drug dissolution rate
and overall drug concentration were found. However, an opti-
mal PEG 6000: drug ratio is likely to exist (Guyot et al., 1995;
Ruan et al., 2005; Save and Venkitachalam, 1992) above which
PEG can no longer improve on this function. We hypothesis
that the enhanced dissolution performance by the lyophilized
mixtures is attributed to the higher porosity that led to
improve wettability of the materials. Such improvement, also,
obscured the ionization effect of the drug. PEG 6000 and Solu-
plus maintained higher drug concentration indicating a
potential to maintain a supersaturated state of drug in the
medium. No significant reduction in the drug concentration
was observed over the experimental time frame. SMX inher-
ently has a fast dissolution rate at these media pH which might
negate the advantages to solid dispersions using these
polymers.
In Fig. 10a, pure NIF exhibited a low dissolution rate in
SIF showing only 19% drug dissolved after three hours. In
water, however, NIF has an improved dissolution rate andPlease cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (exhibited 35% drug dissolved at 180 min. Spray dried NIF
with PEG 6000 provided a higher dissolution rate with incom-
plete drug dissolution at 3 h. Such incomplete dissolution has
been reported elsewhere (Hecq et al., 2005). The sample
allowed more than 40% to be released rapidly in the first
few minutes and then slowly achieved 56% released at
180 min. Soluplus again contributed to a slower dissolution
rate. The drug release profile for Soluplus, however, provided
49% drug release at 180 min, but showed a burst release of
20% drug released in a few minutes.
NIF has a pKa of about 1 and is expected to be mostly ion-
ized at a pH of 1.2. In Fig. 10b, the dissolution rate and the
percentage dissolved at any time for pure NIF in SGF are
higher than found in SIF. This simply confirms that the ion-
ized form of NIF has a higher solubility than its unionized
form. Spray dried NIF with PEG 6000 provided a higher dis-
solution rate with incomplete drug dissolution at 3 h in each
medium. The concentration rapidly achieved greater than
60% in the first few minutes and slowly increased to reach
86% at 180 min. The drug release profile for NIF dispersion
in Soluplus, however, provided 95% release at 180 min in
SGF, but showed a lower level of drug release in the first
few minutes than provided by PEG 6000. It is important to
note that the performance of the spray dried mixtures in the
different media displayed the potential for continued release
of NIF after 180 min.
In Fig. 10c, a rapid dissolution rate was found for the lyo-
philized NIF dispersion in PEG 6000. However, a slight reduc-
tion in NIF concentration after the first reading might indicatevitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Figure 8c FTIR analysis for NIF-polymer mixtures (S denotes spray dried, and L denotes lyophilized).
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Figure 9a Sulfamethoxazole and spray dried SMX with Solu-
plus or PEG 6000 in SIF (n= 3). SMX alone in deionized water
was added for comparison. Error bars represent standard
deviation.
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Figure 9b Sulfamethoxazole and spray dried SMX with Solu-
plus or PEG 6000 in SGF (n= 3). Error bars represent standard
deviation.
16 M.A. Altamimi, S.H. Neauprecipitation of a portion of the released drug. The lyophilized
product showed an enhanced dissolution rate and extent of
drug released in comparison with the performance of the spray
dried mixtures. A similar trend was observed for NIF disper-
sions in Soluplus with a slower release rate followed by an
improved drug release at 180 min.
In Fig. 10d, the dissolution rate and the extent of drug
released for lyophilized NIF-PEG 6000 in SGF are higher than
found in SIF. An enhanced dissolution rate and complete dis-
solution for NIF-Soluplus were observed.Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (Soluplus and PEG 6000 demonstrated tremendous poten-
tial for enhancing the dissolution rate and maintaining the
supersaturated state for the model drugs. That can be attribu-
ted to different reasons. The first reason is the ability of the
polymers to inhibit the crystallization tendency of the amor-
phous materials in supersaturated states (Tanno et al., 2004).
Secondly, polymer behavior in the medium can enhance the
equilibrium concentration of the drug (Konno et al., 2008;
Loftsson et al., 1996), PEG by acting as a cosolvent and Solu-
plus by micelle formation. Furthermore, others suggestedvitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
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Figure 9c Sulfamethoxazole and lyophilized SMX with Solu-
plus or PEG 6000 in SIF (n= 3). Error bars represent standard
deviation.
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Figure 9d Sulfamethoxazole and lyophilized SMX with Solu-
plus or PEG 6000 in SGF (n= 3). Error bars represent standard
deviation.
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Figure 10a Nifedipine and spray dried NIF with Soluplus or
PEG 6000 in SIF (n= 3). NIF alone in deionized water was added
for comparison. Error bars represent standard deviation.
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Figure 10b Nifedipine and spray dried NIF with Soluplus or
PEG 6000 in SGF (n= 3). Error bars represent standard
deviation.
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Figure 10c Nifedipine and lyophilized NIF with Soluplus or
PEG 6000 in SIF (n= 3). Error bars represent standard deviation.
0
20
40
60
80
100
0 50 100 150 200
%
 R
el
ea
se
d
Time (min)
NIF:Soluplus (1:9)
NIF:PEG6000 (1:9)
NIF
Figure 10d Nifedipine and lyophilized NIF with Soluplus or
PEG 6000 in SGF (n= 3). Error bars represent standard
deviation.
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Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (that dispersed mixtures enhanced dissolution rates by
improved wetting of drug due to the inherent higher dissolu-
tion rate of hydrophilic polymers (Fouad et al., 2011; Khan
et al., 2012).
Both Soluplus and PEG 6000 showed an initial burst
release of drug, which is expected from highly soluble polymers
(Khan et al., 2012; Nagy et al., 2012; Karavas et al., 2007).
However, PEG 6000-drug mixtures exhibited a slight reduction
in concentration which might be attributed to precipitation. As
an amphiphilic polymer, Soluplus provided a slower dissolu-
tion rate for SMX and NIF dispersions at this particular mass
ratio, yet this was followed by a higher extent of drug released
than observed with PEG 6000 dispersions. The ionization state
of the drug will also enhance or reduce the dissolution rate and
limit the equilibrium drug concentration based on its inherent
characteristics. This phenomenon is demonstrated well when
using NIF as a model drug. The lyophilized mixtures showed
higher dissolution rates and extents of drug release than each
spray dried counterpart.
4.5. Mathematical models for the release profiles
The kinetic models for the release profiles for different mix-
tures are found in Tables 3 and 4. Release profiles for spray
dried SMX dispersions with Soluplus in simulated intestinal
and gastric fluids are best described by the Ritger-Peppas
equation. This equation utilizes n as the exponent to describe
the release mechanism. The diffusion coefficient n indicates a
Fickian diffusion at a value of 0.45 and case II transport at
a value >0.89. An anomalous release mechanism is expected
when 0.45 < n< 0.89 (Khan et al., 2012; Shoaib et al.,
2006). However, n with values less than 0.45 have beenvitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
Table 3 The kinetic models for dissolution of SMX or release of SMX from Soluplus or PEG 6000 dispersions prepared using spray
drying or lyophilization techniques. ± standard errors (p< 0.05).
Zero Order First Order Higuchi Hixson-Crowell Ritger-Peppas
Materials R2 K0
(min1)
R2 K1
(min1)
R2 KH
(min1/2)
R2 KHC
(min1/3)
R2 n KRP
(minn)
Spray Dried Materials
SMX:PEG 6000
(1:9) (SIF)
– – – – – – – – – – –
SMX (Water) – – – – – – – – – – –
SMX (SIF) – – – – – – – – – – –
SMX:Soluplus
(1:9) (SIF)
0.937 0.0065
± 0.001
0.9725 0.0167
± 0.0016
0.9829 0.0573
± 0.0044
0.9146 0.0110
± 0.0013
0.9996 0.1929
± 0.0059
0.3502
± 0.0064
SMX:PEG 6000
(1:9) (SGF)
– – – – – – – – – – –
SMX (SGF) 0.8185 0.0049
± 0.0013
0.8577 0.0171
± 0.004
0.9224 0.0291
± 0.0049
0.8451 0.0101
± 0.0025
0.9712 0.0497
± 0.005
0.654
± 0.0064
SMX:Soluplus
(1:9) (SGF)
0.9389 0.021
± 0.0031
0.9843 0.0422
± 0.0031
0.9958 0.122
± 0.0046
0.9725 0.0301
± 0.0029
0.9992 0.3399
± 0.006
0.2421
± 0.0034
Lyophilized Materials
SMX:PEG 6000
(1:9) (SIF)
0.9877 0.0594
± 0.0066
0.9981 0.1187
± 0.0052
0.9999 0.1924
± 0.0009
0.9956 0.0851
± 0.0057
0.9988 0.308
± 0.012
0.3689
± 0.0056
SMX:Soluplus
(1:9) (SIF)
– – – – – – – – – – –
SMX:PEG 6000
(1:9) (SGF)
0.9913 0.0191
± 0.001
0.9992 0.0452
± 0.0007
0.9875 0.1079
± 0.007
0.9995 0.0305
± 0.0004
0.9527 0.262
± 0.035
0.320
± 0.026
SMX:Soluplus
(1:9) (SGF)
– – – – – – – – – – –
Table 4 The kinetic models for dissolution of SMX or release of SMX from Soluplus or PEG 6000 dispersions prepared using spray
drying or lyophilization techniques. ± standard errors (p< 0.05).
Zero Order First Order Higuchi Hixson-Crowell Ritger-Peppas
Materials R2 K0
(min1)
R2 K1
(min1)
R2 KH
(min1/2)
R2 KHC
(min1/3)
R2 n KRP
(minn)
Spray Dried Materials
NIF:PEG 6000
(1:9) (SIF)
0.6102 0.0007
± 0.0002
0.6510 0.0013
± 0.0003
0.6890 0.0110
± 0.0023
0.6385 0.0009
± 0.0002
0.7716 0.0677
± 0.0122
0.358
± 0.017
NIF (Water) 0.9437 0.0015
± 0.0001
0.9632 0.0019
± 0.001
0.9984 0.0224
± 0.0003
0.9571 0.0015
± 0.0001
0.9891 0.344
± 0.014
0.0579
± 0.0037
NIF (SIF) 0.9720 0.0010
± 0.0001
0.9798 0.0011
± 0.0001
0.9948 0.0145
± 0.0003
0.9773 0.0009
± 0.0000
0.9990 0.6084
± 0.0091
.0080
± 0.0003
NIF:Soluplus
(1:9) (SIF)
0.9018 0.0016
± 0.0002
0.9318 0.0026
± 0.0002
0.9903 0.0248
± 0.0008
0.9225 0.0018
± 0.0002
0.9833 0.2075
± 0.0097
0.1663
± 0.0068
NIF:PEG 6000
(1:9) (SGF)
0.5809 0.0063
± 0.0027
0.6661 0.0160
± 0.0057
0.7372 0.0468
± 0.0140
0.6375 0.0096
± 0.0036a
0.9679 0.213
± 0.041
0.452
± 0.023
NIF (SGF) 0.9316 0.0012
± 0.0001
0.9485 0.0014
± 0.0001
0.9978 0.0187
± 0.0003
0.9431 0.0011
± 0.0001
0.9970 0.511
± 0.013
0.0173
± 0.0010
NIF:Soluplus
(1:9) (SGF)
0.9721 0.0074
± 0.0005
0.9962 0.0139
± 0.0004
0.9971 0.0654
± 0.0014
0.9914 0.0092
± 0.0003
0.9811 0.2761
± 0.0019
0.195
± 0.011
Lyophilized Materials
NIF:PEG 6000
(1:9) (SIF)
– – – – – – – – – – –
NIF:Soluplus
(1:9) (SIF)
0.7526 0.0017
± 0.0003
0.8138 0.0032
± 0.0005
0.9158 0.0271
± 0.0026
0.7943 0.0021
± 0.0003
0.9901 0.1695
± 0.0060
0.2553
± 0.0064
NIF:PEG 6000
(1:9) (SGF)
– – – – – – – – – – –
NIF:Soluplus
(1:9) (SGF)
0.9163 0.0304
± 0.0065
0.9719 0.0812
± 0.0098
0.9818 0.134
± 0.028
0.9567 0.0479
± 0.0072
0.9944 0.218
± 0.017a
0.4521
± 0.0097
a For (p> 0.05).
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Table 5 The release profile comparisons for SMX-polymer mixtures.
Reference
material
SMX(SIF) SMX(SGF) SMX:
Soluplus
(1:9) (SIF)
SMX:
PEG6000
(1:9) (SIF)
SMX:
PEG6000
(1:9) (SIF)
SMX:
Soluplus
(1:9) (SIF)
SMX:
PEG6000
(1:9) (SIF)
SMX:
Soluplus
(1:9) (SIF)
SMX:
PEG6000
(1:9) (SGF)
SMX:
Soluplus
(1:9) (SGF)
SMX:
PEG6000
(1:9) (SGF)
SMX:
Soluplus
(1:9) (SGF)
SMX:
PEG6000
(1:9) (SGF)
SMX:
Soluplus
(1:9) (SGF)
Spray dried materials
f2 72.87 31.85 24.55 34.18 32.84 22.37 66.10 51.21
Lyophilized materials
f2 43.93 63.07 37.88 40.22 37.26 46.76 40.05 64.38
Table 6 The release profile comparisons for NIF-polymer mixtures.
Reference
material
NIF(SIF) NIF(SGF) NIF:
Soluplus
(1:9) (SIF)
NIF:
PEG6000
(1:9) (SIF)
NIF:
PEG6000
(1:9) (SIF)
NIF:
Soluplus
(1:9) (SIF)
NIF:
PEG6000
(1:9) (SIF)
NIF:
Soluplus
(1:9) (SIF)
NIF:
PEG6000
(1:9) (SGF)
NIF:
Soluplus
(1:9) (SGF)
NIF:
PEG6000
(1:9) (SGF)
NIF:
Soluplus
(1:9) (SGF)
NIF:
PEG6000
(1:9) (SGF)
NIF:
Soluplus
(1:9) (SGF)
Spray dried materials
f2 21.76 28.93 12.11 16.21 22.85 31.68 30.47 29.12
Lyophilized materials
f2 15.46 21.05 7.41 5.97 20.70 22.03 29.47 18.91
In vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions 19reported (Khan et al., 2012; Shoaib et al., 2006). The n values
were found to be 0.1929 in SIF and 0.3399 in SGF, which sug-
gest a combination of diffusion, relaxation and erosion
mechanisms.
For lyophilized SMX-PEG 6000 dispersions, the n values for
drug release in SIF andSGFwere found to be 0.3083 and 0.2887,
respectively. A complex release mechanisms is also expected
based on these n values. Also, such close n values might indicate
that the medium does not substantially impact the release rate.
Spray dried NIF-Soluplus mixtures were described, rather
well, using the Higuchi diffusion model. On the contrary,
NIF-PEG 6000 dispersed mixtures were poorly described by
all the employed release models indicating a complicated release
mechanism. When release data for lyophilized NIF-Soluplus
dispersions are considered, theHiguchi andRitger-Peppasmod-
els showed the best fit.However, the n value below 0.45 indicates
mixed release mechanisms. The fit of the kinetic models to the
release data indicates not only dissolution, but also diffusion,
erosion, and swelling might be taking place during drug release.
These potential mixed mechanisms exerted a considerable
impact on drug release profiles.
4.6. Comparison of release profiles
Comparison between release profiles can be executed using
analysis of variance (ANOVA) between two or multiple data
points (MANOVA). However, the f2, similarity test, is usually
preferable when comparing the entire dissolution release pro-
file. Furthermore, the similarity test has been adapted by the
FDA for just this sort of in vitro dissolution release profile
comparison (Costa and Sousa Lobo, 2001; Polli et al., 1997).Please cite this article in press as: Altamimi, M.A., Neau, S.H. Investigation of the in
when prepared using spray drying or lyophilization. Saudi Pharmaceutical Journal (One of the disadvantages of this method is the dependency
on the dissolution profile length. It might show similarity at
certain time points and dissimilarity at different time points
between the same two dissolution profiles. However, the values
will be hovering around 50 (Pillay and Fassihi, 1998), the cut-
off for similarity of the two profiles.
The dissolution profiles were compared using this test to
elucidate the impact of the selected polymer, preparation tech-
niques, and the chosen medium, see Tables 5 and 6.
The spray dried SMX dispersion with Soluplus or PEG
6000 exhibited a similarity in their dissolution profiles when
placed in either SIF or SGF, f2 = 66.10 and 51.21, respec-
tively. However, only the lyophilized SMX-Soluplus disper-
sion showed similarity (f2 = 64.38) in the two release media.
On the other hand, NIF dispersions did not show any similar-
ity across the media or techniques. This suggests that the sim-
ilarity that was found for SMX mixture is due to the close
resemblance of SMX behavior to that of its dispersions. This
is not surprising in the light of the solubility of SMX under
the release conditions.
5. Conclusions
NIF and SMX solid dispersions were successfully prepared by
spray drying and lyophilization using Soluplus and PEG
6000. Thermal analyses showed no melting endotherm indicat-
ing the absence of crystallinity at higher polymer concentra-
tions. Drugs dispersed in Soluplus demonstrated a spherical
shape when spray dried.
The drug dissolution rates were significantly enhanced.
However, NIF dissolution rate was improved to a greatervitro performance diﬀerence of drug-Soluplus and drug-PEG 6000 dispersions
2016), http://dx.doi.org/10.1016/j.jsps.2016.09.013
20 M.A. Altamimi, S.H. Neauextent due to its inherent low solubility in the two release
media. Dispersions with PEG 6000 had a faster dissolution
rate due to its hydrophilic nature. However, Soluplus exhib-
ited a tendency to maintain higher drug concentrations over
time. The dissolution profiles of the different mixtures proved
to be dissimilar across the preparation techniques and/or
media.
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